Drug shortage: Kay-Cee-L syrup to be out of stock from late September

Healthcare providers are advised to prioritise remaining supplies of Kay-Cee-L syrup for patients requiring doses of less than 12mmol of potassium 

The Department of Health and Social Care (DHSC) has issued an alert regarding a significant shortage of Kay-Cee-L syrup, a medication used for the treatment of hypokalaemia or potassium deficiency.

Primary and Secondary care providers are informed that Kay-Cee-L (potassium chloride 5mmol/5ml) syrup will be out of stock from late September 2024, with the resupply date yet to be confirmed.

The National Patient Safety Alert indicated that the supply disruption is caused by “an amendment to the manufacturing process, requiring re-formulation, and revalidation of the product.”

It recommended Sando-K ® (potassium bicarbonate 400mg and potassium chloride 600mg) effervescent tablets as an alternative option to support an increase in demand. One effervescent tablet contains 12mmol potassium.

Moreover, the DHSC noted that unlicensed potassium chloride oral solutions manufactured within the UK are available through Specials manufacturers.

Specials manufacturers like Nova Laboratories, Target Healthcare and Rokshaw Laboratories have confirmed to the department that they can manufacture potassium chloride oral solution in various strengths.

The DHSC has directed prescribers to collaborate with local pharmacy teams to ensure that orders are placed within appropriate time frames as lead times may vary.

“Specials are unlicensed medicines manufactured in the UK. The composition and strength of these presentations vary compared with the UK licensed product, so clinicians should refer to the Product Quality statement.” the alert noted.

Prescribers are also required to consider the relevant guidance and NHS Trust or local governance procedures before prescribing an unlicensed medicine.

Meanwhile, healthcare Providers are advised to prioritise remaining supplies of Kay-Cee-L syrup for patients requiring doses of less than 12mmol of potassium and where other preparations are not suitable.

Healthcare providers have been advised to refrain from initiating Kay-Cee-L syrup for new patients and to review all current patients on the medication to determine if potassium supplementation remains necessary.  If considered necessary, they should switch to an alternative treatment, ensuring that there are no intolerances to excipients.

For more information, read the alert here.